Human-relevant drug-discovery platform combining patient-derived brain organoids engineered with disease-driving mutations and AI-driven foundation models to enable high-throughput screening, disease-network mapping, target validation, and translational CNS drug candidate generation. Designed to accelerate disease-modifying therapies and responder stratification for rare genetic neurodevelopmental and dopamine-related disorders and to enable high-value biopharma collaborations.